

1 **Genome sequencing of the first SARS-CoV-2 reported from**
2 **patients with COVID-19 in Ecuador.**

3

4 Sully Márquez¹, Belén Prado-Vivar^{1,2}, Juan José Guadalupe⁴, Bernardo
5 Gutierrez^{4,6}, Manuel Jibaja⁵, Milton Tobar⁵, Francisco Mora⁷, Juan Gaviria⁷, María
6 García⁷, Franklin Espinosa⁷, Edison Ligña⁷, Jorge Reyes^{7,9}, Verónica Barragán¹,
7 Patricio Rojas-Silva¹, Gabriel Trueba¹, Michelle Grunauer^{3,8}, Paúl Cárdenas^{1,2*}

8

9 ¹Universidad San Francisco de Quito, COCIBA, Instituto de Microbiología

10 ²Universidad San Francisco de Quito, Centro de Bioinformática

11 ³Universidad San Francisco de Quito, Escuela de Medicina, COCSA

12 ⁴Universidad San Francisco de Quito, COCIBA, Laboratorio de Biotecnología Vegetal

13 ⁵Unidad de Cuidados Intensivos, Hospital Eugenio Espejo, Quito

14 ⁶Department of Zoology, University of Oxford

15 ⁷Hospital General Sur de Quito, IESS

16 ⁸Unidad de Cuidados Intensivos, Hospital de los Valles, Quito

17 ⁹ Universidad Central del Ecuador, Facultad Ciencias Químicas

18

19

20

21 *Correspondence: pacardenas@usfq.edu.ec, tel.: +593-22971700 ext. 1517

22

23

24

25

26

27

28

29

30

31

32

33

34

35 **Abstract**

36 SARS-CoV-2, the etiological agent of COVID-19 was first described in Wuhan in
37 December 2019 and has now spread globally. Ecuador was the second country in
38 South America to report confirmed cases. The first case reported in Quito, the capital
39 city of Ecuador, was a tourist who came from the Netherlands and presented
40 symptoms on March 10th, 2020 (index case). In this work we used the MinION platform
41 (Oxford Nanopore Technologies) to sequence the metagenome of the bronchoalveolar
42 lavage (BAL) from this case reported, and subsequently we sequenced the whole
43 genome of the index case and other three patients using the ARTIC network protocols.
44 Our data from the metagenomic approach confirmed the presence of SARS-CoV-2
45 coexisting with pathogenic bacteria suggesting coinfection. Relevant bacteria found in
46 the BAL metagenome were *Streptococcus pneumoniae*, *Mycobacterium tuberculosis*,
47 *Staphylococcus aureus* and *Chlamydia* spp. Lineage assignment of the four whole
48 genomes revealed three different origins. The variant HEE-01 was imported from the
49 Netherlands and was assigned to B lineage, HGSQ-USFQ-018, belongs to the B.1
50 lineage showing nine nucleotide differences with the reference strain and grouped with
51 sequences from the United Kingdom, and HGSQ-USFQ-007 and HGSQ-USFQ-010
52 belong to the B lineage and grouped with sequences from Scotland. All genomes show
53 mutations in their genomes compared to the reference strain, which could be important
54 to understand the virulence, severity and transmissibility of the virus. Our findings also
55 suggest that there were at least three independent introductions of SARS-CoV-2 to
56 Ecuador.

57 **Key words:** SARS-CoV2, MinION sequencing, COVID-19, metagenomic analysis,
58 whole genome

59

60 **IMPORTANCE** COVID-19, an infectious disease caused by SARS-CoV-2, has spread
61 globally including Latin American countries including Ecuador. The first strain of SARS-
62 CoV-2 sequenced was from Wuhan, which is considered as the reference strain. There
63 were no data about the SARS-CoV-2 lineages in Ecuador, and the purpose of this
64 study was to find out the origin of the different lineages circulating in the population. We
65 also were interested in the mutations present in these genomes as they can influence
66 virulence, transmission and infectivity.

67

68 **INTRODUCTION**

69 SARS-CoV-2, the etiologic agent of COVID-19, has spread globally reaching all
70 continents^{1,2}. Ecuador was the second country in South America, after Brazil, to report
71 its first case on 29 February 2020³. The number has grown since, reaching 39,098
72 laboratory-confirmed cases and 3,358 deaths until May 31st, 2020⁴. The pandemic
73 has had a severe impact in Ecuador, as death excess estimates suggest that up to
74 182.44 people per million inhabitants may have died since the first COVID19 case⁵,
75 making Ecuador the country with the highest mortality rate in South America.

76 Quito, the capital city of Ecuador, was the second city to report COVID-19
77 cases after Guayaquil. After a severe wave of cases in Guayaquil during the early
78 stages of the outbreak, Quito currently reports the largest number of COVID-19 daily
79 cases in the country. The first case in Quito was diagnosed initially in the Sucumbíos
80 province, while the patient was doing tourism, and was subsequently brought to a third-
81 level hospital in the capital. The patient is originally from the Netherlands and was
82 diagnosed by the Health Ministry on March 10th, 2020. His condition deteriorated while
83 in Sucumbíos, prompting his transfer to Quito where he was admitted into the Intensive
84 Care Unit of the Eugenio Espejo Hospital. After 32 days, the patient recovered and
85 returned to his native country. Currently, local authorities have confirmed 3676 cases⁴
86 and widespread community transmission is actively happening.

87 Understanding the local epidemiology of SARS-CoV-2 can greatly be enhanced
88 from understanding the virus evolution. It is therefore relevant to invest in SARS-CoV-2
89 genome sequencing as it could help to establish the origin of the pathogen ⁶, its
90 transmission across different regions ⁷, the genetic diversity of the circulating strains in
91 the population and to identify notable mutations ⁸. Additionally, key biological aspects
92 such as virulence, transmissibility and infectivity of the circulating strains can be
93 investigated, when combined with clinical data from the patients ⁷. Around 35,473
94 genome sequences of SARS-CoV-2 have been reported from countries around the
95 world and are available in GenBank and the GISAID (Global Initiative on Sharing All
96 Influenza Data) repository ⁹.

97 In this work we describe the first four SARS-CoV-2 whole genome sequences
98 obtained from Ecuador. We also report the metagenomic analysis of the first COVID-19
99 patient diagnosed in Quito. Both approaches were performed using the portable
100 MinION platform (Oxford Nanopore Technologies).

101 **MATERIALS AND METHODS**

102 **Ethics**

103 This study used excess respiratory samples after being officially confirmed with positive
104 COVID19 diagnosis. Ethical approval for all samples was given by CEISH-USFQ
105 (Comité de ética de investigación en seres humanos-USFQ): IE-JP067-2020-CEISH-
106 USFQ.

107 **Epidemiological information and sample collection**

108 Samples from the four patients were collected in Hospital Eugenio Espejo (HEE) or
109 Hospital IESS Sur (HGSQ), two public third-level hospitals at Quito, Ecuador. Sample
110 positivity for SARS-CoV-2, using standard RT-PCR approach, was officially reported to
111 hospitals by the Ecuadorian Ministry of Public Health (MSP) and National Institute of

112 Public Health and Research (INSPI). Sample HEE-01 was a bronchi-alveolar lavage
113 (BAL) from a patient of Dutch origin in his late fifties who presented symptoms during a
114 visit to the Sucumbios province and then transferred to the HEE intensive care unit
115 (ICU) in Quito. This patient was the first confirmed COVID-19 case in Quito. Samples
116 HGSQ-USFQ-018, HGSQ-USFQ-007 and HGSQ-USFQ-010 were all nasopharyngeal
117 swabs. HGSQ018 was collected from a 27 years old male patient who presented
118 severe COVID-19 symptoms after a visit to Guayaquil and was admitted to the
119 pneumology unit at HGSQ. Sample HGSQ-USFQ-007 was collected from a 40 years
120 old male patient that had no history or contact with a COVID-19 patient, presented
121 severe COVID19 symptoms and was admitted to ICU at HGSQ. Sample HGSQ-USFQ-
122 010 was collected from a 39 years old male patient that had contact with patient
123 HGSQ-USFQ-007 and was also admitted to ICU. The BAL sample was collected in a
124 sterile tube with 2X DNA/RNA Shield (Zymo), and nasopharyngeal swabs were
125 submerged in 1X DNA/RNA Shield (Zymo) to ensure virus inactivation and to preserve
126 the genetic material. Samples were transported immediately at 4°C to the Institute of
127 Microbiology at USFQ (IM-USFQ) in a sealed container with all the biosecurity and
128 containment measures recommended by the CDC of the USA
129 (<https://www.fda.gov/media/134922/download>).

130 **RNA extraction**

131 The genetic material from samples was extracted in a biosafety type II chamber with
132 HEPA filters in the Virology Laboratory of the Microbiology Institute (IM) at USFQ. Two
133 different sequencing approaches were performed with the extracted RNA:
134 metagenomics with sample HEE01 and whole genome sequencing with samples
135 HEE01, HGSQ-USFQ-018, HGSQ-USFQ-007 and HGSQ-USFQ-010. QIAamp® Viral
136 RNA Extraction Kit (Qiagen) was used to extract RNA from the HEE1 sample that was
137 used for the metagenomics approach. Briefly, 250 µl of BAL sample and 560 µl of AVL
138 lysis buffer were incubated for 1 hour, then manufacturer RNA kit instructions were

139 followed. Sample was eluted in a final volume of 70 μ l. RNA was immediately purified
140 using RNA Clean and Concentrator kit (Zymo), 14 μ l of purified ARN were used for
141 retrotranscription of RNA to cDNA following the RNA Viral Metagenomics MinION One-
142 Pot Sequencing Protocol from the genomics department of Public Health England^{10,11}.

143 SV Total RNA Isolation System kit (Promega, USA) was used to extract RNA from
144 samples used for the whole genome sequencing approach. A predigestion step was
145 added to the RNA extraction protocol of the bronchoalveolar fluid (BAL) sample as
146 follows. Before nucleic acid extraction, 280 μ l of the Bronchoalveolar fluid (BAL) sample
147 was predigested with 360 μ l of PureLink™ Genomic Lysis Buffer and 20 μ l of
148 proteinase K. The mix was incubated at 55°C for 10 minutes, with vortexing every 5
149 minutes (Life Technologies, USA). All RNA extractions were performed following
150 manufacturer instructions and eluted in a final volume of 50 μ l. Total RNA was
151 quantified using QuBit (Thermo Fisher Scientific) with a Qubit RNA Assay Kit (Thermo
152 Scientific, Invitrogen, Carlsbad, CA, USA). Retrotranscription of RNA to cDNA was
153 carried out using the Protocol of the Public Health England Genomics Lab^{10,11} at the
154 USFQ Bioinformatics Center.

155 **Viral whole genome sequencing approach**

156 Primer Scheme approach developed by the ARTIC network for nCoV-2019 (Robertson,
157 2020) using the V1 primer sets to generate an amplicon tiling path across the viral
158 genome¹². cDNA MinION library preparation was performed using the Rapid
159 Barcoding kit (SQK-RBK004) following manufacturer instructions and then loaded into
160 a MinION flow cell (FLO-MIN 106). Base calling of FAST5 files was performed using
161 Guppy (version 3.4.5) (Wick, et al 2019), and the RAMPART software (v1.0.5) from the
162 ARTIC Network (<https://github.com/artic-network/rampart>) was used to monitor
163 sequencing in real-time. Sequence quality scoring, demultiplexing and adapter removal
164 was performed with the NanoPlot¹³ and Porechop algorithms respectively. The ARTIC

165 Network bioinformatics pipeline was used for variant calling, and the reads were
166 mapped against the reference strain Wuhan-Hu-1 (GenBank accession number
167 MN908947), to generate consensus genomes. The genome was uploaded to the CoV-
168 GLUE resource ¹⁴, to determine the epidemiological linkage of circulating SARS-CoV-2
169 variants.

170 **Metagenomic approach and bioinformatic analysis.** cDNA MinION library
171 preparation was performed using the Rapid Barcoding kit (SQK-RBK004) following
172 manufacturer instructions. The resulting library was loaded on an Oxford MinION
173 flowcell (FLO-MIN 106) and sequenced using the MinKNOW version 4.05, for 24
174 hours. Basecalling and quality control analysis was performed using Guppy (version
175 3.4.5) and NanoPlot (version 1.29.0) respectively¹³. Adapters and barcodes were
176 removed from the MinION reads using Porechop (version 0.2.4)
177 (<https://github.com/rrwick/Porechop>). Taxonomic classification of the sequences was
178 performed using the Kaiju platform¹⁵. A SARSCoV-2 consensus sequence was
179 obtained by mapping reads against the reference strain Wuhan-Hu-1 (GenBank
180 accession number MN908947) using minimap2 (version 2.14-r883)¹⁶. Finally,
181 Samtools (version 1.9) (<http://samtools.github.io>) and Tablet alignment viewer (version
182 1.19.09.3) (<https://ics.hutton.ac.uk/tablet>) were used to visualize the mapped
183 sequence.

184 **RESULTS**

185 **Metagenomic sequencing confirms SARS-CoV-2 infection in patient HEE-01 and**
186 **possible bacterial coinfection.**

187 The metagenomic analysis found a total of 206,111 DNA sequences with 43,603,091
188 bases. Viral sequences represented 0.9%, of which 83% corresponded to non-
189 assigned coronavirus and 17% were identified as SARS coronaviruses (Figure 1). The
190 sequences assigned to coronavirus were extracted and mapped using the Wuhan-Hu-1

191 reference genome (GenBank accession number MN908947). A sequence similarity of
192 99.68% was found with this sequence with 100% query coverage. Additionally, a
193 phylogenetic tree was generated with the sequences found and the reference strains
194 used in GenBank NCBI. The phylogenetic alignment grouped the query sequence with
195 the ORF1AB segment of the virus polyprotein (it encodes replication genes). The
196 metagenome sequences are publicly available at
197 <https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA613094> (Accession:
198 PRJNA613094).

199 Several bacterial and eukaryotic sequences related to the patient's respiratory
200 microbiota were identified by metagenomics. The most relevant taxa found were
201 *Streptococcus pneumoniae*, *Mycobacterium tuberculosis*, *Staphylococcus aureus* and
202 *Chlamydia* spp. We did not identify any particular clinically relevant fungus. To
203 complement the metagenomic approach we carried on with the whole genome
204 sequencing of the current sample and additionally with 3 more additional samples from
205 severely ill patients diagnosed in March.

206 **Complete genome sequencing revealed multiple entries of the virus to Ecuador**

207 Whole genome sequencing of the first case of COVID-19 in Quito revealed it to be an
208 imported case from Europe (strain named HEE-01). Compared with the Wuhan-Hu-1
209 reference strain, HEE-01 shows only two nucleotide differences that include one amino
210 acid replacement. HEE-01 was assigned to the B lineage and grouped with sequences
211 from the Netherlands (Figure 2). Strain HGSQ-USFQ-018 was obtained from a case
212 detected in Quito, but the infection was presumably acquired in Guayaquil. It shows
213 nine nucleotide differences with the reference genome (Table 1). This genome is
214 placed in the B.1 lineage and grouped with genomes from other European countries
215 (Figure 2). Finally, HGSQ-USFQ-007, a community acquired infection in Quito, and the
216 sequence from an epidemiologically-linked contact (HGSQ-USFQ-010) were also

217 placed in the B lineage. Both sequences have multiple differences compared to the
218 reference strain, including 17 amino acids replacement and one amino acid deletion
219 (Table 1).

220

221 **DISCUSSION**

222 The mitigation of the spread of SARS-CoV-2 has been unsuccessful in most
223 South American countries. Countries like Ecuador, where the population, despite
224 shocking examples in other cities like Guayaquil, continues to react in disbelief at an
225 imminent risk. It is now when scientific research is needed to guide the authorities to
226 develop correct public health policies. In this study, we were able to uncover the first 4
227 SARS-CoV-2 whole genome sequences from Ecuador using the portable low-cost
228 MinION platform (Oxford Nanopore). Genome sequences, from the first COVID19
229 case reported in Quito, have few differences compared to the reference strain (Wuhan-
230 Hu-1), and is grouped within lineage B near sequences from patients in the
231 Netherlands. This finding confirms that the patient most likely acquired the infection in
232 his country of origin. Metagenome sequencing of the patient's BAL revealed possible
233 bacterial coinfection as several of the microorganisms are not considered members of
234 the core lower airways bacterial microbiota¹⁷. As consequence, the encountered
235 bacteria were probably contributing to the patient's severe condition. Metagenomic
236 analysis could be crucial in COVID-19 cases because it adds valuable information
237 about concurrent pulmonary pathogens that can aggravate the clinical condition¹⁸⁻²⁰.

238 acquired the infection at the community level, either in Guayaquil or Quito. All
239 three patients presented severe respiratory symptoms. Sequence recovered from a
240 patient that got infected in Guayaquil grouped in lineage B.1, suggesting a second
241 introduction of the virus into the country. Finally, the virus sequences recovered from
242 two patients infected in Quito had marked differences with the previous sequences,

243 suggesting a third introduction of the virus to the country. These sequences were
244 identical between them, which was expected since the patients were family members,
245 developed symptoms at the similar time and lived together. Furthermore, the distinct
246 set of mutations from these sequences was analyzed in a separate study which reports
247 a potential virulence factor not previously described, which is associated with inhibition
248 of the interferon response *in vitro*²¹. Community acquired transmission is now
249 widespread in Ecuador and more samples from community acquired infections are
250 needed in order to inform analyses of the local epidemiology of the virus. Comparing
251 these genomes will allow us to provide a more accurate estimate of the arrival times
252 and routes of the virus into certain areas, and to better understand how it is locally
253 spreading and evolving. Revealing the information contained in the SARS-CoV-2 virus
254 genome sequences is a robust tool to understand the epidemiology of COVID-19
255 locally and contribute to the global panorama.

256 The current pandemic is unlikely to be the last, and it is therefore essential to
257 improve the response capacity of our public health systems and to implement and
258 strengthen continuous scientific research programs. Only in this way we will be able to
259 better understand these types of threats, act based on evidence, and thus reduce their
260 impact.

261 **ACKNOWLEDGEMENTS**

262 This work was funded by Universidad San Francisco de Quito and CADDE project
263 (www.caddecentre.org/). P.C. is funded by NIH FIC D43TW010540 Global Health
264 Equity Scholars.

265 We acknowledge the submitting authors and institutions of the sequences of SARS
266 CoV 2 from GISAID Database.

267 **AUTHOR CONTRIBUTIONS**

268 Conceptualization: M.J., G.T., M.G., P.C. Methodology: S.M., B.P.-V., J.J.G., M.T.,
269 P.C. Software: B.P.-V., V.B., P.C. Validation: B.P.-V., V.B. and P.C. Formal analysis
270 and investigation: V.B., P.R.-S. and P.C. Writing - Original Draft: P.R.-S. and P.C.
271 Writing - Review & Editing: All authors. Visualization: V.B. and P.C. and M.A.
272 Supervision: G.T. Funding acquisition: M.G, G.T. & P.C.

273 **REFERENCES**

- 274 1. Rodríguez-Morales AJ, Gallego V, Escalera-Antezana JP, et al. COVID-19 in
275 Latin America: The implications of the first confirmed case in Brazil. *Travel Med*
276 *Infect Dis*. Published online 2020. doi:10.1016/j.tmaid.2020.101613
- 277 2. Rodríguez-Morales AJ, MacGregor K, Kanagarajah S, Patel D, Schlagenhauf P.
278 Going global – Travel and the 2019 novel coronavirus. *Travel Med Infect Dis*.
279 Published online 2020. doi:10.1016/j.tmaid.2020.101578
- 280 3. Ecuador confirma su primer caso de coronavirus. National Geographic en
281 español. Published 2020. Accessed March 30, 2020.
282 [https://www.ngenespanol.com/el-mundo/ecuador-confirma-su-primer-caso-de-](https://www.ngenespanol.com/el-mundo/ecuador-confirma-su-primer-caso-de-coronavirus/)
283 [coronavirus/](https://www.ngenespanol.com/el-mundo/ecuador-confirma-su-primer-caso-de-coronavirus/)
- 284 4. SITUACIÓN NACIONAL POR COVID-19 (CORONAVIRUS) - INFOGRAFÍA
285 N°094. Ministerio de Salud Pública Ecuador. Published 2020.
286 [https://www.gestionderiesgos.gob.ec/wp-](https://www.gestionderiesgos.gob.ec/wp-content/uploads/2020/05/INFOGRAFIA-NACIONALCOVI-19-COE-NACIONAL-31052020-08h002.pdf)
287 [content/uploads/2020/05/INFOGRAFIA-NACIONALCOVI-19-COE-NACIONAL-](https://www.gestionderiesgos.gob.ec/wp-content/uploads/2020/05/INFOGRAFIA-NACIONALCOVI-19-COE-NACIONAL-31052020-08h002.pdf)
288 [31052020-08h002.pdf](https://www.gestionderiesgos.gob.ec/wp-content/uploads/2020/05/INFOGRAFIA-NACIONALCOVI-19-COE-NACIONAL-31052020-08h002.pdf)
- 289 5. Max Roser, Hannah Ritchie EO-O and JH. Coronavirus Pandemic (COVID-19).
290 Our World in Data. Published 2020. <https://ourworldindata.org/coronavirus>
- 291 6. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin
292 of SARS-CoV-2. *Nat Med*. Published online 2020. doi:10.1038/s41591-020-
293 0820-9
- 294 7. Kupferschmidt K. Genome analyses help track coronavirus' moves. *Science* (80-
295). Published online 2020. doi:10.1126/science.367.6483.1176
- 296 8. Shen Z, Xiao Y, Kang L, et al. Genomic diversity of SARS-CoV-2 in Coronavirus
297 Disease 2019 patients. *Clin Infect Dis*. Published online 2020.
298 doi:10.1093/cid/ciaa203
- 299 9. GISAID. GISAID - EpiCoV. Published 2020. www.epicov.org
- 300 10. Greninger AL, Naccache SN, Federman S, et al. Rapid metagenomic
301 identification of viral pathogens in clinical samples by real-time nanopore
302 sequencing analysis. *Genome Med*. Published online 2015. doi:10.1186/s13073-
303 015-0220-9
- 304 11. Kafetzopoulou LE, Efthymiadis K, Lewandowski K, et al. Assessment of
305 metagenomic Nanopore and Illumina sequencing for recovering whole genome
306 sequences of chikungunya and dengue viruses directly from clinical samples.
307 *Eurosurveillance*. Published online 2018. doi:10.2807/1560-
308 7917.ES.2018.23.50.1800228
- 309 12. Quick J, Grubaugh ND, Pullan ST, et al. Multiplex PCR method for MinION and
310 Illumina sequencing of Zika and other virus genomes directly from clinical
311 samples. *Nat Protoc*. Published online 2017. doi:10.1038/nprot.2017.066
- 312 13. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. NanoPack:
313 Visualizing and processing long-read sequencing data. *Bioinformatics*. Published
314 online 2018. doi:10.1093/bioinformatics/bty149
- 315 14. Singer JB, Thomson EC, McLauchlan J, Hughes J, Gifford RJ. GLUE: A flexible
316 software system for virus sequence data. *BMC Bioinformatics*. Published online
317 2018. doi:10.1186/s12859-018-2459-9

- 318 15. Menzel P, Ng KL, Krogh A. Fast and sensitive taxonomic classification for
319 metagenomics with Kaiju. *Nat Commun*. Published online 2016.
320 doi:10.1038/ncomms11257
- 321 16. Li H. Minimap2: Pairwise alignment for nucleotide sequences. *Bioinformatics*.
322 Published online 2018. doi:10.1093/bioinformatics/bty191
- 323 17. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic
324 airways. *PLoS One*. 2010;5(1):e8578. doi:10.1371/journal.pone.0008578
- 325 18. Moore SC, Penrice-Randal R, Alruwaili M, et al. Amplicon based MinION
326 sequencing of SARS-CoV-2 and metagenomic characterisation of
327 nasopharyngeal swabs from patients with COVID-19. *medRxiv*. Published online
328 2020. doi:10.1101/2020.03.05.20032011
- 329 19. Arabi YM, Al-Omari A, Mandourah Y, et al. Critically Ill patients with the middle
330 east respiratory syndrome: A multicenter retrospective cohort study. *Crit Care*
331 *Med*. Published online 2017. doi:10.1097/CCM.0000000000002621
- 332 20. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99
333 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
334 study. *Lancet*. Published online 2020. doi:10.1016/S0140-6736(20)30211-7
- 335 21. Konno Y, Kimura I, Urie K, et al. SARS-CoV-2 ORF3b is a potent interferon
336 antagonist whose activity is further increased by a naturally occurring elongation
337 variant. *bioRxiv*. Published online 2020. doi:10.1101/2020.05.11.088179
- 338
- 339

340 **Figures and tables legends:**

341

342 **Figure 1. Krona chart summarizing the percentage of sequences assigned to**
343 **Coronavirus in the metagenome.** Coronavirus sequences represented 0.036% of all
344 microorganisms.

345

346

347 **Figure 2. Maximum parsimony phylogenetic tree.** Ecuadorian sequences are
348 highlighted in bold. Lineage assignments are highlighted in similar colors: lineage A
349 (Green color palette) and lineage B (Brown color palette).

350

351 **Table1.** Mutations found in four SARS-CoV-2 Genomes from Ecuador compared to
352 Wuhan-Hu-1 (GenBank accession number MN908947)

353




Table1. Mutations found in four SARS-CoV-2 Genomes from Ecuador compared to Wuhan-Hu-1 (GenBank accession number MN908947).

Genome Sequence ID	Genome Sequence GISAID ID	Lineage	Gene	Mutation	Amino acid	Type
HEE-01	EPI_ISL_417482	B	ORF1ab	T514C	-	-
			S	A25182T	E1207V	Transversions
HGSQ-USFQ-018	EPI_ISL_422563	B.1	ORF1ab	C3037T	no	Transition
			ORF1ab	C4010T	L431F	Transition
			ORF1ab	C14408T	P323L	Transition
			ORF1ab	C18555T	no	-
			S	A23403G	D614G	Transition
			ORF3a	A25983G	no	-
			N	G28881A	R203K	Transition
			N	G28882A	no	-
			N	G28883C	G204R	Transversions
HGSQ-USFQ-007	EPI_ISL_422564	B	ORF1ab	A1996C	-	-
	and		ORF1ab	C1997T	no	Transition
HGSQ-USFQ-010	EPI_ISL_422565	B	ORF1ab	T11737G	N255K	Transversions
			ORF1ab	T20497A	N255K	Transversions
			S	G22424T	A288S	Transversions
			S	C24418T	no	Transition
			ORF3a	A25505C	Q38P	Transversions
			ORF3a	G25647T	L85F	Transversions
			ORF3a	T25676C	L95S	Transition
			ORF3a	C25678T	L96F	Transition
			ORF3a	C25692T	no	Transition
			ORF3a	T25695G	-	-
			ORF3a	C25708T	L106F	Transition
			ORF3a	C25710T	no	Transition
			ORF3a	T25711C	Y107H	Transition
			ORF3a	C25728T	no	Transition
			ORF3a	A25741G	S117G	Transition
			ORF3a	A25756G	R122E	Transition
			ORF3a	G25757A	no	Transition
			ORF3a	A25764T	-	-
			ORF3a	T25779G	-	-
			ORF3a	G25781A	C130*	Transition
			ORF3a	C25782A	-	-
			ORF3a	G25879A	V163T	Transition
			ORF3a	T25880C	no	Transition
			ORF3a	C25883A	T164N	Transversions
			ORF3a	T25885G	S165A	Transversions
			ORF8	A28035G	R48G	Transition
			ORF8	A28037G	no	Transition
			ORF8	G28038T	V49L	Transversions
			ORF8	C28076T	no	Transition
			ORF8	T28078C	V62A	Transition

Lineages were assigned using Pangolin COVID-19 Lineage Assigner (pangolin.cog-uk.io).